Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced financial results for its third quarter ended September 30, 2025 and the ...

Vertex ( ($VERX) ) has shared an update. On October 30, 2025, Vertex‘s Board of Directors authorized a stock repurchase program for up to $150 ...

Vertex, Inc. shares have plunged over 60% YTD, but valuation is now compelling after a post-earnings dip. Learn more about VERX stock here.

The stock, which is down more than 61% in 2025, sold off after reporting a Q3 EPS beat missing on revenue expectations.

Vertex Minerals Ltd. ( ($AU:VTX) ) has issued an announcement. Vertex Minerals Limited has commenced underground ore production at the Reward Gold ...

If you're an individual retail investor searching for healthcare stocks you can buy and hold for at least 20 years, here are ...

- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex (VRTX) to submit first module before end of year - - Second pivotal ...

- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Updated data from RUBY-3 ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein ...

To topple access barriers to Vertex Pharmaceuticals’ potentially lifesaving, yet often out-of-reach cystic fibrosis therapy ...